Loading...
•
Jun 30, 2023
Eagle Q2 2023 Earnings Report
Delivered a strong second quarter with impressive earnings and revenue.
Key Takeaways
Eagle Pharmaceuticals reported a strong second quarter with total revenue of $64.6 million and net income of $5.2 million, or $0.39 per basic and diluted share. The company's marketed drugs across oncology and its hospital business performed well, leading to raised full-year guidance and resumption of the share repurchase program.
Total revenue for Q2 2023 was $64.6 million.
Q2 2023 net income was $5.2 million, or $0.39 per basic and diluted share.
Adjusted non-GAAP net income for Q2 2023 was $15.5 million, or $1.18 per basic and diluted share.
Company reiterates raised full-year guidance of adjusted non-GAAP EBITDA of $78.0-$84.0 million and adjusted non-GAAP earnings per share of $4.40-$4.70.
Forward Guidance
The Company reiterated its recently announced raised guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...